Oncology & advanced therapy in China: access, eligibility & costs (2026)
China runs one of the world's largest CAR-T ecosystems, with multiple approved products at treatment costs far below U.S. list prices. Access starts with a specialist records review, not a price quote — and honest screening matters most, because many inquiries don't qualify, and we say so early rather than let false hope drag on.
Public reference costs
| PROCEDURE | TYPICAL U.S. PRICE | CHINA COST (REFERENCE · EST.) | TIMELINE |
|---|---|---|---|
| CAR-T therapy (all-in episode) | $273,000–475,000+ | Reference: ≈ $150,000–180,000 (Yicai, 2025) | quoted case-by-case after specialist review |
| Proton/heavy-ion therapy | — | individual quote | after records review |
| Remote specialist second opinion | — | from $399 | 5–7 business days |
CAR-T reference range is public reporting of Chinese all-in treatment episodes (Yicai, Dec 2025); U.S. range is industry-reported product list price plus typical hospital episode costs. Your figure — if you qualify — comes only from an itemized quote after specialist review of your records.
How access actually works
Records review first
Diagnosis, pathology, and prior treatment lines go to a hematology-oncology team through our Remote Second Opinion pathway. Anyone who quotes you a CAR-T price before a specialist has read your records is guessing.
Eligibility decision
Screening is strict — indication, prior treatment lines, and fitness are all checked before anything else happens. CAR-T inquiries have our highest decline rate of anything we coordinate; being told "not eligible, and here's why" within days beats months of false hope.
Logistics only after confirmation
Only after a specialist confirms eligibility do we talk logistics: the manufacturing timeline (CAR-T is built from your own cells), the inpatient window for infusion and monitoring, and a stay of several weeks.
The Boao Lecheng special-access pathway
The Hainan Boao Lecheng zone is China's special medical-access area — it permits certain internationally approved therapies and devices, including 512 approved-abroad drugs and devices as of 2025 (Qiushi, 2025), that aren't yet licensed elsewhere in the country. For eligible oncology and advanced-therapy cases, that can open options still working through mainland approval, coordinated the same way as every other case: records review first, eligibility decided by physicians, logistics after.
What availability means — and doesn't
Therapies available in China — including Boao special-access — may not be FDA-approved. Availability is a statement about Chinese regulatory access, not an endorsement of efficacy. All eligibility decisions are made solely by licensed physicians. See the Medical disclaimer.
Oncology FAQ
Can I join a clinical trial in China as a foreigner?
Is quality comparable to U.S. CAR-T programs?
How long does the whole process take?
What does the free eligibility check involve?
Find out if you qualify — before you spend anything.
Free records review by a hematology-oncology team — a direct yes, no, or what we still need, usually within days.